Latest news with #AlzheimersDisease
CBS News
16 hours ago
- Entertainment
- CBS News
Seth Rogen, Teri Hatcher among many celebrities sharing real-life stories of caregiving
Caregiving is a tough job that affects everyone, regardless of their notoriety or financial status. That's why some big names are using their platforms to help others who are going through the same thing. Actor and comedian Seth Rogen and his wife, Lauren Miller Rogen, who's also a screenwriter and actress, produced a powerful and very personal documentary about her mother, Adele, and her life with Alzheimer's disease, a journey that started in 2012 when the couple was just in their 20s. "You're not alone if you are experiencing something similar," Seth Rogen recently told CBS News New York's Jennifer Bisram. "In making this film, I think the balance was how do you show the reality of such a harsh disease but still find the optimism," Lauren added. But behind the scenes they share a commonality with the estimated 53 million family caregivers across the country, including 2.2 million in New York -- being there for aging parents. "It isn't just the person who's sick; it's the whole family, it's the children," Seth Rogen said. "I really feel so strong that my mom, who was a teacher, would want people to be educated about this disease and the realities of caring for someone with it," Lauren said. Sadly, Adele lost her battle with the disease in 2020, but her life and legacy lives on with Hilarity for Charity, an organization that focuses on brain health education and gives caregivers financial and physical relief. "Our resources made our situation much more livable, which is why giving grants for in-home care for people was a big priority for our charity, because we just saw it could make a big change instantaneously," Seth Rogen said. Craig Robinson, the executive director of the National Association of Basketball Coaches, and his sister, former first lady Michelle Obama, lost their mother last year. They talked about their loss and caregiving struggles with the Rogens on their podcast, "IMO." "I could empathize with her feeling like she wanted to maintain as much control, but she was making it hard, and this is with resources," Obama said. "This is something that knows no income, it knows no race, it knows no ethnicity. It is going to hit everyone. It made sense for us to share with the rest of the world," Robinson said. Robinson said his family had a plan in place, including cameras in their mother's home and professionals helping out, but said the anxiety was a relentless storm and the emotional toll was a constant battle. "My mom definitely did not want to go into a nursing home or assisted-living facility," Robinson said. "So any time an emergency popped up, we had to get there." "What my wife and I are doing for our kids, we are laying out a whole plan so we have an easy path to follow," he told CBS News New York. Actress Teri Hatcher, who starred for years on "Desperate Housewives," is helping her viewers navigate caregiving with cooking and a little humor through her #SANDWICHED series on Instagram. "I can't make my dad's dementia go away. I can get him into an art class. I can try to get him to stop eating whipped cream for breakfast, but can't do it all," Hatcher said. "You can't reason with people that just aren't making good decisions, because they can't. ... My mom still wants to be in control of everything." Her parents are both 90 and she's their only child. She said she calls her videos a venting space and encourages self care. "This is life. This is what happens and part of my #SANDWICHED series is about having a community, where, as I said, maybe we can't fix it, but maybe we can feel not alone," Hatcher told CBS News New York. It's also personal for David Hyde Pierce, known for his role in the sitcom "Frasier." "My grandfather had Alzheimer's and my own dad before he died had probably a mix of Alzheimer's and vascular dementia. That's how I got involved with the Alzheimer's association," he said. At a recent CaringKind gala in New York City, celebrities, including "Sex in the City" star Chris Noth, used their platforms to raise money and bring awareness to brain health and aging diseases. "It's something that doesn't get talked about enough," Noth said. Emma Hemming Willis, who has been open about husband Bruce Willis' dementia diagnosis, started Make Time Wellness, an organization designed to help women prioritize their mental, physical and overall well-being during caregiving. "When I began struggling with my own brain fog and burnout, I realized no one was talking about it and, worse, we were being dismissed by our doctors and the medical community," she said. Beth Finkel, executive director of AARP, formerly the American Association of Retired Persons, in New York state, explained why it's even hard for people with money to be caregivers. "Everyone needs help. You don't realize it because it's a world you don't navigate until you are in the middle of it. Then you go, 'Oh my gosh, what do I do now?'" Finkel said. Experts say compassion has no income bracket and the capacity for care has no social boundaries. "Emotionally, it's a roller coast for everyone. That mother, father or spouse that you knew as a strong, independent, really smart person, all of a sudden they can't remember anything," Finkel said. The Rogens are offering advice, like getting a genetics test if an aging disease runs in your family, and to talk about your caregiving journey. "I think it's very therapeutic to connect with somebody you see who's going through the same thing as you," Seth Rogen said. Diverse caregiving experiences and challenges affect everyone, famous or not. Help is available for those in need. For more on Hilarity for Charity and respite relief, please click here.
Yahoo
a day ago
- Business
- Yahoo
EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition NUTLEY, N.J., July 21, 2025 /PRNewswire/ -- Eisai Inc. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) protofibril* antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27 - 31. Eisai will present 21 oral presentations, 24 posters, three (3) symposia and two (2) lecanemab product theaters. Key Oral Lecanemab Presentations Four-year Data: On Wednesday, July 30, as part of the "Developing Topics Session: Innovative Therapeutic Approaches" (8:00 – 8:45 AM EDT), initial four-year findings will be presented on lecanemab from the Phase 3 Clarity AD Open-Label Extension in Early Alzheimer's Disease trial. Subcutaneous Maintenance Dosing: A Featured Research Session on Wednesday, July 30 (9:00 – 10:30 AM EDT) will include data on the potential of a new and convenient option for ongoing lecanemab treatment, the subcutaneous formulation for maintenance dosing. Real World Case Studies: A Developing Topics Session on Sunday, July 27 (9:00 – 10:30 AM EDT) will include data on real-world case studies and patient pathway learnings from diverse U.S. clinical settings two years post-approval of lecanemab. Key Lecanemab Poster Presentation A Poster Presentation on Monday, July 28 (viewing available from 7:30 AM – 4:15 PM EDT) will share findings on cerebrospinal fluid (CSF) samples collected from the Clarity AD trial and analyzed using the novel, sensitive immunoassay developed to measure Aβ protofibrils in CSF. Key Oral E2814 Presentation A Featured Research Session on Wednesday, July 30 (4:15 – 5:45 PM EDT) will include findings from the Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer's Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial. "The data presented at AAIC 2025 will highlight long-term findings from lecanemab's open-label extension trial, real-world lecanemab case studies as well as results on a subcutaneous formulation and dosing regimen that may offer patients more flexibility to continue treatment to fight Alzheimer's disease," said Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. "We will also share preliminary results from the DIAN-TU-001 NexGen Trial, exploring etalanetug with background lecanemab therapy to slow or prevent the progression of Alzheimer's disease. As we gain more experience using dual-acting lecanemab in different clinical settings and continue to explore new avenues to improve the diagnosis and treatment of Alzheimer's disease, we are hopeful about the future. We remain committed to patients and their loved ones who are impacted by this progressive, relentless disease, caused by a continuous underlying neurotoxic process that begins before and continues after plaque is removed from the brain." Key Featured Research Sessions Featured Research Session (FRS), #1-31-FRS-A: Anti-Amyloid Therapies in Clinical Practice: Real World Evidence and Implementation Consideration 4:15 - 5:45 PM EDT, Sunday, July 27 Session Program Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results (Abstract ID 103048) Featured Research Session, #4-13-FRS-C: Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's Disease 9:00 - 10:30 AM EDT, Wednesday, July 30 Session Program Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations (Abstract ID 104694) Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer's Disease (Abstract ID 104693) Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation (Abstract ID 104691) Subcutaneous Lecanemab: Potential Benefits and Place in Therapy (Abstract ID 104695) Featured Research Session, #4-31-FRS-B: Anti-Tau Etalanetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer's Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial 4:15 - 5:45 PM EDT, Wednesday, July 30 Session Program DIAN-TU-001 Trial (Tau NexGen) Rationale and Enrollment Experience (Abstract ID 105298) Baseline Participant Clinical Characteristics in the DIAN-TU-001 Trial (Abstract ID 105299) Baseline Imaging Characteristics of Participants in the Phase II/III DIAN-TU- 001 Tau NexGen Trial for Dominantly Inherited Alzheimer's Disease (Abstract ID 105301) Lecanemab in DIAD: 6-Month Amyloid PET Results from the DIAN-TU-001 Trial (Abstract ID 105303) Safety of Lecanemab After 6-Month Treatment in the DIAN-TU-001 Trial (Abstract ID 105304) Key Developing Topics Sessions Developing Topics On Real-World Data 8:00 - 8:45 AM EDT on Sunday, July 27 Session Program Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery in Early Alzheimer's Disease Patients (Abstract ID 108809) Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway Learnings from Diverse US Clinical Settings 9:00 - 10:30 AM EDT on Sunday, July 27 Session Program Real-World Use of Lecanemab in Patients with Early Alzheimer's Disease in the United States: A Case Series Review (Abstract ID 108599) Real-World Use of Lecanemab with Consideration of Race, Ethnicity and Geographical Diversity (Abstract ID 108602) Real-World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy (Abstract ID 108603) Physician Satisfaction with Lecanemab in Early Alzheimer's Disease: Real- World Insights from Prescribers in the United States (Abstract ID 108605) Real-World Insights on the Lecanemab Patient Pathway in Early Alzheimer's Disease in the United States (Abstract ID 108606) Blood-Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer's Disease in the United States (Abstract ID 108607) Developing Topics On Innovative Therapeutic Approaches 8:00 - 8:45 AM EDT, Wednesday, July 30 Session Program The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer's Disease: Initial Findings from the 48-Month Analysis (Abstract ID 108905) Additional Featured Research and Developing Topics Sessions Biomarkers July 28 (Mon.) 9:00 – 10:30 AM EDT Featured Research Session, #2-17-FRS-A: Sex Specific Risk And Protective Factors in Alzheimer's Disease Sex-Stratified GWAS Meta-Analyses Reveal Novel Sex-Specific Association with CSF Biomarkers of Alzheimer's Disease (Abstract ID 102560) Lecanemab July 29 (Tues.) 2:00 – 3:30 PM EDT Developing Topics Session: Developing Topics On Tau Biomarkers Variations in Plasma p-Tau217 by Sociodemographic Factors Across World Regions in a Preclinical AD Clinical Trials Program: The AHEAD 3-45 Study (Abstract ID 108909) Clinical Trials July 30 (Weds.) 2:00 – 3:30 PM EDT Featured Research Session, #4-26-FRS-A: Innovative Use of Statistical Models and Machine Learning to Enhance AD Clinical Trials Baseline Predictions of PACC Progression Trajectories in Preclinical AD Improve the Precision and Power of Treatment Effect Assessments (Abstract ID 99560) Poster Presentations Asset/Project,Presentation Date and Time** Title, Abstract Number Lecanemab July 27 (Sun.) Results from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous Autoinjector (Abstract ID 106273) Lecanemab July 27 (Sun.) Delphi Consensus for Implementation of Anti-Amyloid mAb Initiation in Private Practice Neurology: Preliminary Recommendations from Experienced Providers (Abstract ID 108789) Lecanemab July 28 (Mon.) Target Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity AD (Abstract ID 108918) Lecanemab July 28 (Mon.) Understanding Real-World Clinical Experience with Lecanemab: Capturing the Patient and Care Partner Voice Through Social Media Listening (Abstract ID 102018) Lecanemab July 29 (Tues.) Patient and Care Partner Expectations and Emotional Experiences of Lecanemab: A Social Media Listening Study (Abstract ID 101001) Lecanemab July 29 (Tues.) Lecanemab Real-World Use Perspectives from a New England Alzheimer's Disease Center: A Retrospective Chart Review (Abstract ID 101388) Lecanemab July 30 (Weds.) Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease Treatment Center (Abstract ID 101400) E2025 July 29 (Tues.) Quantification of EphA4 Turnover Rate and Subsequent Validation of Target Engagement for E2025, a Novel Anti-EphA4 Antibody, in Human Neural Cells (Abstract ID 96834) E2814 July 30 (Weds.) E2814 Mitigates Tau Pathology: Inhibiting Tau Uptake and Promoting MTBR- Tau Clearance Through Microglial Pathways in vitro (Abstract ID 102696) Biomarkers and Imaging July 27 (Sun.) External Validation of Joint Propagation Model-Based Tau PET CenTauR Units (Abstract ID 106362) Biomarkers and Imaging July 28 (Mon.) Identifying Differentially Expressed Proteins Between Amyloid Positive and Amyloid Negative Subjects Based on Alamar Multiplex Assay Data Using MissionAD Samples (Abstract ID 107031) Biomarkers and Imaging July 29 (Tues.) Influence of Demographics and Scan Time on MK6240 Off-Target Signal and Reference Region Selection (Abstract ID 100424) Biomarkers July 27 (Sun.) Observational Study Evaluating Blood-Based Biomarker Use for Confirmatory Alzheimer's Disease Diagnosis in Real-World Clinical Practice Within the United States (Abstract ID 99857) Biomarkers July 28 (Mon.) A De Novo-Assisted Strategy to Identify Novel IncRNA-Encoded Peptides in Cerebrospinal Fluid of Demented Subjects With or Without Amyloid Positivity (Abstract ID 106893) Biomarkers July 28 (Mon.) Impact of Blood-Based Biomarkers on Access to Alzheimer's Disease Treatments: A Simulation Study in Japan (Abstract ID 102553) Biomarkers July 29 (Tues.) Implementation Science Study Evaluating the Real-World Use of Blood-Based Biomarkers as Confirmatory Diagnostic Tools for Alzheimer's Disease in the United States (Abstract ID 99804) Biomarkers July 29 (Tues.) Characterization of Lewy Body Copathology in Early AD Clinical Trial Population Demonstrates Similarities and Differences Compared to Natural History Studies in Alzheimer's Disease Patients (Abstract ID 107102) Biomarkers July 30 (Weds.) Value of Blood-Based Biomarker Testing to Diagnose, Identify and Monitor Patients with Alzheimer's Disease: A Structured Literature Review (Abstract ID 99842) Biomarkers July 30 (Weds.) Alzheimer's Disease Molecular Subtypes in a Clinical Trial Cohort (Abstract ID 105257) General AD July 27 (Sun.) Operational Consideration and Best Practices for Implementation of an Early Alzheimer's Disease Patient Care Pathway (Abstract ID 108093) General AD July 27 (Sun.) Estimating Clinical Transitions in Patients with Alzheimer's Using Instrumental Activities of Daily Living (IADL) (Abstract ID 107058) General AD July 28 (Mon.) Staging Alzheimer's Disease Using the Functional Assessment Screening Tool (FAST): A Crosswalk with the Montreal Cognitive Assessment (MoCA) (Abstract ID 107045) General AD July 29 (Tues.) Time to Alzheimer's Disease Diagnosis in Japan: A Retrospective Observational Study (Abstract ID 97026) General AD July 30 (Weds.) Alzheimer's Disease Staging by Instrumental Activities of Daily Living (IADL): A Crosswalk with the Montreal Cognitive Assessment (MoCA) (Abstract ID 107009) **Poster viewing time is set from 7:30 AM – 4:15 PM EDT on the date of presentation Eisai-Sponsored Symposia Asset/Project,Presentation Date and Time Title General AD July 28 (Mon.) 6:00 – 7:30 PM EDT Smoldering Alzheimer's Disease: The Ongoing Benefit of Addressing Multiple Pathologies General AD July 30 (Weds.) 6:15 – 7:45 AM EDT Unlock Your Brain: Exploring Alzheimer's Disease from the Inside Out General AD July 30 (Weds.) 6:00 – 7:30 PM EDT Brain Health Navigator—Ensuring Efficient and Effective Alzheimer's Disease Diagnostic and Clinical Care Pathways Eisai-Sponsored Product Theaters Asset/Project,Presentation Date and Time Title Lecanemab July 27 (Sun.) 12:25 – 1:05 PM EDT Early Diagnosis, Early Treatment: Identifying Patients for Greater Benefit in Mild Cognitive Impairment Due to Alzheimer's Disease Lecanemab July 28 (Mon.) 12:25 – 1:05 PM EDT Best Practices in Early Alzheimer's Disease Care: Creating a Plan from Screening Through Long-Term Treatment Product theaters will feature presentations based on real-world clinical experience with lecanemab - providing attendees with an opportunity to hear best practices and expert guidance on using this therapy. This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval. * Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2 MEDIA CONTACTSEisai Inc. (U.S.)Julie Edelman+1-862-213-5915Julie_Edelman@ [Notes to editors] About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved and being marketed in the U.S.,3 Japan,4 China,5 South Korea,6 Hong Kong,7 Israel,8 the United Arab Emirates,9 the United Kingdom,10 Mexico,11 Macau,12 Oman, Taiwan,13 European Union,14 Qatar, Singapore15 and Thailand16 for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Eisai has submitted applications for approval of lecanemab in 11 countries and July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy. About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. References Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi: 10.1038/s41467-021-23507-z. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. U.S. Food and Drug Administration. 2023. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. Last accessed: July 2025. Reuters. 2023. Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen. Last accessed: July 2025. The Pharma Letter. 2024. Brief - Alzheimer drug Leqembi now approved in China. Last accessed: July 2025. Pharmaceutical Technology. 2024. South Korea's MFDS approves Eisai-Biogen's LEQEMBI for Alzheimer's. Last accessed: July 2025. Pharmaceutical Technology. 2024. Hong Kong approves Leqembi for Alzheimer's treatment. Last accessed: July 2025. Israel Ministry of Health. The Israeli Drug Registry. Leqembi. Last accessed: July 2025. United Arab Emirates Ministry of Health & Prevention. 2024. Registered Medical Product Directory. Leqembi. Last accessed: July 2025. BioSpace. 2024. Leqembi authorized for early Alzheimer's disease in Great Britain. Last accessed: July 2025. COFEPRIS authorizes innovative treatment for Alzheimer's patients. Available at: Last accessed: July 2025. Macau Special Administrative Region Drug Search. Last accessed: July 2025. Taiwan Food and Drug Administration Assessment Report. Last accessed: July 2025. European Medicines Agency. Leqembi | European Medicines Agency (EMA). Last accessed: July 2025. Health Sciences Authority. Last accessed: July 2025. Thailand Food and Drug Administration, Ministry of Public Health. Last accessed: July 2025. View original content to download multimedia: SOURCE Eisai Inc.
Yahoo
3 days ago
- Business
- Yahoo
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best . In a report released on July 13, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb Company (NYSE:BMY), setting a price target of $34.00. A pharmacy shelves stocked with pharmaceutical drugs awaiting distribution. The analyst based the rating on the company's current market standing and future prospects, reasoning that a key point of concern is Bristol-Myers Squibb Company's (NYSE:BMY) reliance on Cobenfy. Cobenfy is an approved drug for schizophrenia and is now being tested for Alzheimer's Disease Psychosis (ADP). However, the analyst stated that while ADP has considerable potential market with no approved therapies available, it is uncertain whether Cobenfy will succeed in the domain, as it depends on the results of the ongoing Phase 3 trials. Flynn also reasoned that the initial uptake for the drug has been slower than expected for the treatment of schizophrenia, which may falter investor confidence in Cobenfy's potential to drive positive future revenue growth. Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience. While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Medscape
5 days ago
- Health
- Medscape
Career Pivot: A Physician's Guide to What's Next
Challenging Cases in Behavioral Symptoms of Alzheimer's Disease: A Medical Simulation for Diagnosis and Management 1.0 CME Credits
Medical News Today
14-07-2025
- Health
- Medical News Today
What are the different types of dementia?
Dementia is an umbrella term for conditions that result in a loss of memory, problem-solving, and other thinking abilities. There are many different forms of dementia, and they occur due to changes in certain brain regions. Dementia is a general term that refers to a group of conditions that result in a progressive decline of brain functioning. These conditions can cause problems with memory, thinking, language, mood, emotions, and the ability to perform daily typically occurs due to changes in the brain that impact nerve cells or neurons, damaging a person's cognitive abilities. This article explores five different types of diseaseAccording to the Alzheimer's Association, Alzheimer's disease is the most common type of dementia, accounting for roughly 60% to 80% of cases of dementia in the United are still unsure of the exact cause of Alzheimer's disease. However, it likely relates to changes in the brain, such as shrinking of certain regions, inflammation, and blood vessel damage that results in problems with memory and thinking indicates that many different factors, such as genetics and lifestyle behaviors, contribute to Alzheimer's disease. However, age is the biggest risk factor for the condition, with most people developing Alzheimer's disease at 65 years of age or disease progresses in stages, with worsening symptoms. Common symptoms can include:memory problemsthinking and reasoning difficultieslanguage problemsmood changesvision and hearing changesVascular dementiaVascular dementia is the second most common type of dementia, according to the Alzheimer's Society. It describes a form of dementia that occurs due to restrictions in blood flow to the brain. Inadequate blood flow can damage and eventually kill cells in the brain, resulting in a decline in thinking skills. People over the age of 65 are more likely to develop vascular experts refer to conditions that interrupt the flow of blood and oxygen to the brain as vascular contributions to cognitive impairment and dementia. There are different types of vascular dementia that occur due to different blood supply problems to the brain. For example, vascular dementia can occur following a of vascular dementia can vary depending on the severity of blood vessel damage and the part of the brain it affects. Symptoms may be most obvious following an event that damages blood vessels, such as a stroke. For example, the Alzheimer's Association notes that post-stroke changes in thinking and perception can include:confusiondisorientationdifficulty speaking or understanding speechdifficulty balancing and walking problemsnumbness or paralysis on one side of the face or bodyCommon early signs of damage to blood vessels in the brain may include:impaired planning and judgmentuncontrolled laughing and cryinginability to pay attentionimpaired function in social settingstrouble finding the right wordsLewy body dementiaLewy body dementia is the third most common form of dementia. It occurs due to brain deposits of a protein known as alpha-synuclein, or Lewy bodies. There are two types of Lewy body dementia: dementia with Lewy bodies and Parkinson's disease are currently unsure why Lewy bodies develop in the brain, or exactly how they cause dementia. However, the Alzheimer's Society notes that these protein deposits appear to disrupt the typical functioning of nerve cells, interfering with communication between brain body dementia usually develops over many years. These protein deposits can develop in the brain for a long time before a person presents with symptoms. Although it is possible for younger people to have Lewy body dementia, it usually begins at age 50 or older. Symptoms of Lewy body dementia can include:changes in thinking and reasoningmemory lossvisual hallucinationsproblems staying awakesleep disruptionParkinsonism, such as slow movement, tremors, or rigidityFrontotemporal dementiaFrontotemporal dementia (FTD) is a form of dementia that tends to occur at a younger age than other dementias. Roughly 60% of people with FTD are 45 to 64 years old. The condition was formerly known as Pick's disease, but health experts changed the name to reflect the brain areas the disease impacts. The Alzheimer's Association notes that while researchers do not fully understand the cause of FTD, many people with this form have proteins, known as tau and TDP-43, inside the nerve cells in their brain. The buildup of these proteins damages the neurons and eventually causes cell deathAccording to the Alzheimer's Society, there are two main types of FTD. Behavioral variant FTD describes when damage occurs to the frontal lobes. These lobes are present behind the forehead and help with processing information. As such, behavioral variant FTD can cause symptoms with behavior and progressive aphasia FTD refers to damage to the temporal lobes. These lobes are present on eitherside of the head and help with the understanding of speech. As such, damage to the temporal lobes can cause difficulty with language. This can cause symptoms like difficulty formulating words in a sentence, or affect a person's dementiaIn some cases, people may develop multiple types of dementia. This is known as mixed dementia. When an older adult develops dementia, it is likely due to a combination of different types, rather than just a single type. According to the Alzheimer's Society, roughly 1 in 10 people with a diagnosis of dementia may receive a diagnosis of mixed it can be difficult to diagnose mixed dementia, as a doctor is likely to base their diagnosis on the main type of disease they think is present and causing symptoms. The Alzheimer's Association notes that a combination of Alzheimer's disease and vascular dementia is the most common such, there is no fixed set of symptoms for mixed dementia. The symptoms a person experiences can vary depending on the type of dementia they The treatment a person receives will depend on the type of dementia they have. Currently, there is no cure for dementia. However, treatments are available to help slow the progression of the may include a combination of medications and non-medical treatment, such as therapies and person-centered care. These treatments may help to improve or stabilize memory, thinking skills, and behavioral can also help address other issues that may affect everyday tasks, such as problems with mobility, speech, and swallowing.»FIND CARE:Find a dementia specialist in your area is an umbrella term for conditions that cause a gradual decline in thinking processes, such as memory, problem-solving, and speech. There are many different forms of dementia, which develop for different reasons. Some common types of dementia include Alzheimer's disease, vascular dementia, and Lewy body dementia occurs due to changes in the brain that damage and kill nerve cells. This results in a variety of symptoms, such as memory loss, difficulty concentrating, and problems with language and who suspects themselves or a loved one is experiencing dementia should speak with a healthcare professional.
